Skip to main content

Table 5 Comparison of CDKN2A-positive and CDKN2A-negative breast cancer cases

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Parameters   p16-positive p16-negative p
   n = 157 n = 2912  
age (mean)   44.35 44.34 0.9
age group 20–30 6/157 (3.82%) 51/2912 (1.75%) 0.11
  31–40 21/157 (13.38%) 501/2912 (17.2%) 0.25
  41–50 130/157 (82.80%) 2360/2912 (81.04%) 0.66
histology "low grade" 32/108 (29.63%) 637/2012 (31.66%) 0.74
  "high grade" 15/108 (13.88%) 303/2012 (15.06%) 0.85
  medullary 6/108 (5.55%) 112/2012 (5.57%) 0.99
  lobular 18/108 (16.66%) 388/2012 (19.28) 0.58
  tubulo-lobular 6/108 (5.55%) 89/2012 (4.42%) 0.75
  DCIS 16/108 (14.81%) 170/2012 (8.45%) 0.04
  other 15/108 (13.88%) 313/2012 (15.56%) 0.74
  no data or unknown 12/108 (11.11%) 225/2012 (11.18%) 0.89
pre-operative positive 37/151 (24.5%) 675/2012 (24.5%) 0.99
chemotherapy     
ER positive 61/91 (67.03%) 1085/1698 (63.9%) 0.58
tumour size <1 cm 9/99 (9.09%) 185/1767 (10.47%) 0.87
  1–1.9 cm 43/99 (43.43%) 798/1767 (45.16%) 0.76
  2–4.9 cm 46/99 (46.46%) 742/1767 (42%) 0.72
  >5 cm 1/99 (1.01%) 42/1767 (2.38%) 0.73
nodal status positive 37/100 (37%) 752/1801 (41.75%) 0.4
multi-centricity present 18/90 (20%) 340/1898 (17.91%) 0.58
laterality present 5/138 (3.62%) 88/2573 (3.42%) 0.96
family history positive (+) 11/146 (7.5%) 240/2658 (9%) 0.64
  1. For all comparisons, except age, bilaterality and family history, cases with pre-operative chemotherapy were excluded. Family history refers to a first-degree relative affected with breast cancer